This review summarizes the role of long noncoding RNAs (lncRNAs) as biomarkers in glioblastoma multiforme (GBM), a highly aggressive brain tumor with poor prognosis. LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into proteins and are involved in various cellular processes, including gene regulation, chromatin modification, and epigenetic mechanisms. They are expressed in different tissues and have been implicated in the development and progression of GBM. The review highlights the importance of lncRNAs as potential therapeutic targets and diagnostic biomarkers for GBM, as their expression can be detected in biological fluids such as blood, plasma, and urine. The review presents a systematic overview of lncRNAs associated with GBM, focusing on their expression patterns, functions, and potential as biomarkers. It also discusses the molecular mechanisms by which lncRNAs regulate gene expression and their involvement in various biological processes, including cell proliferation, apoptosis, invasion, angiogenesis, and resistance to therapy. The review identifies several lncRNAs that are dysregulated in GBM and may serve as biomarkers for diagnosis, prognosis, and treatment response. These include lncRNAs such as ADAMTS9-AS2, ANRIL, CASC2, CRNDE, DGCR5, GAS5, LINC00467, and LINC00641. The review also discusses the potential of lncRNAs as biomarkers in liquid biopsy, where their expression can be analyzed in blood or other bodily fluids to detect GBM and monitor treatment response. The review emphasizes the need for standardized nomenclature and further research to better understand the role of lncRNAs in GBM and their potential as biomarkers for diagnosis and treatment.This review summarizes the role of long noncoding RNAs (lncRNAs) as biomarkers in glioblastoma multiforme (GBM), a highly aggressive brain tumor with poor prognosis. LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into proteins and are involved in various cellular processes, including gene regulation, chromatin modification, and epigenetic mechanisms. They are expressed in different tissues and have been implicated in the development and progression of GBM. The review highlights the importance of lncRNAs as potential therapeutic targets and diagnostic biomarkers for GBM, as their expression can be detected in biological fluids such as blood, plasma, and urine. The review presents a systematic overview of lncRNAs associated with GBM, focusing on their expression patterns, functions, and potential as biomarkers. It also discusses the molecular mechanisms by which lncRNAs regulate gene expression and their involvement in various biological processes, including cell proliferation, apoptosis, invasion, angiogenesis, and resistance to therapy. The review identifies several lncRNAs that are dysregulated in GBM and may serve as biomarkers for diagnosis, prognosis, and treatment response. These include lncRNAs such as ADAMTS9-AS2, ANRIL, CASC2, CRNDE, DGCR5, GAS5, LINC00467, and LINC00641. The review also discusses the potential of lncRNAs as biomarkers in liquid biopsy, where their expression can be analyzed in blood or other bodily fluids to detect GBM and monitor treatment response. The review emphasizes the need for standardized nomenclature and further research to better understand the role of lncRNAs in GBM and their potential as biomarkers for diagnosis and treatment.